NeurAxis Inc (NRXS) Forward Price-to-Revenue Multiple
The projected P/S for NeurAxis, Inc. (NRXS) on GURU.Markets demonstrates current dynamics, where 12.20 captures the actual state of the parameter. Growth is supported by a strong ethical culture and the commitment of bioengineers to the mission of helping children. Stability is provided by the defensive qualities of neurostimulation, which remains in demand across all economic cycles. Development potential relies on physician loyalty to these unique devices, despite the slow expansion of insurance coverage.
Summary analytical data breakdowns for NeurAxis Inc (NRXS)
- market price and analyst price targets:
- market capitalization details:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital NeurAxis, Inc.|NRXS - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio NeurAxis, Inc.|NRXS - Company Total Debt Obligations|Debt to Book Capitalization Ratio NeurAxis Inc|NRXS - Company Long-Term Indebtedness|Company Short-Term Debt NeurAxis|Quick Liquidity Indicator neuraxis.com
- financial results and valuation multiples details:
NRXS - Company Profit|Expected Profit NeurAxis, Inc.|NRXS - Business Payback Period|Future Price to Earnings NeurAxis, Inc|NRXS - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple NeurAxis Inc|NRXS - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months NeurAxis|NRXS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months neuraxis.com|NRXS - Earnings per share increase in current year|Net earnings per share growth forecast for next year NeurAxis, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:NRXS (NeurAxis)
The forward P/S ratio determines the market value of NeurAxis, Inc. (NRXS) relative to its expected annual sales, measuring the revenue volume priced into its capitalization. By analyzing this forward price-to-sales chart, an investor can assess the impact of non-invasive neurostimulation systems for pediatrics on investment attractiveness: a low multiple would confirm the business is undervalued given stable clinic demand for gastrointestinal treatment equipment.
Competitor analysis for NeurAxis, Inc.
Price-to-Projected Revenue Ratio Biogen BIIB|Market Cap to Expected Sales Ratio Neurocrine (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Corp)|ACAD: Forward P/S Multiple|XENE - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Viking Therapeutics, Inc.|Market Cap to Projected Revenue SUPN (Supernus Pharmaceuticals, Inc.)|Forward P/S Multiple CPRX|Forward Price-to-Revenue Multiple Denali Corp DNLI|Harmony Biosciences - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio biohavenpharma.com (BHVN)|AMLX - Price-to-Projected Revenue Ratio|TRVI (Trevi Therapeutics Inc) - Market Cap to Projected Revenue|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Anavex Life Sciences Corp - Forward Price to Sales|Forward Price-to-Revenue Multiple CBLL|Market Cap to Projected Revenue PRTA (Prothena Corporation)|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|Market Cap to Expected Sales Ratio Annexon Biosciences|Price-to-Projected Revenue Ratio Omeros OMER|NGNE: Market Cap to Projected Revenue|AC Immune - Forward P/S Multiple|Market Cap to Future Revenue Ratio voyagertherapeutics.com|NMRA (Neumora Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Scilex Holding (SCLX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|ACOG: Forward Price to Sales|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|IKT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|ASRT: Market Cap to Projected Revenue|Coya - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vistagen Therapeutics|OVID (ovidrx.com) - Forward Price-to-Revenue Multiple|acumenpharm.com (ABOS) - Forward P/S Multiple|Price-to-Projected Revenue Ratio CervoMed|ATHE: Forward Price to Sales|Forward P/S Multiple CLNN|Forward P/S Multiple pepgen.com (PEPG)|Jupiter Neurosciences Inc - Forward Price-to-Revenue Multiple|RLMD: Market Cap to Projected Revenue|Annovis Bio - Forward P/S Multiple|Market Cap to Expected Sales Ratio Grace Therapeutics, Inc. GRCE|Firefly Neuroscience Inc (AIFF) - Price-to-Projected Revenue Ratio|KLTO - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple NRSN|RVPH: Forward Price to Sales|Forward P/S Multiple MTVA|Market Cap to Expected Sales Ratio heliusmedical.com|Price-to-Projected Revenue Ratio Passage Bio PASG|NEUP: Market Cap to Projected Revenue|Minerva Neurosciences - Forward P/S Multiple|athira.com (ATHA) - Forward Price-to-Revenue Multiple|ADXN (Addex Therapeutics Ltd) - Forward Price-to-Revenue Multiple|ALZN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Projected Revenue PTIX (Protagenic)|Price-to-Projected Revenue Ratio Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Forward Price to Sales|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|BCLI: Market Cap to Projected Revenue|CARA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Chromocell CHRO|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ITCI|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Marinus Pharmaceuticals Inc MRNS|Forward Price-to-Revenue Multiple NKGN (NKGen)|Forward P/S Multiple NeuroBo Pharma (NRBO)|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|Forward Price to Sales SNPX|TRVN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vigil Neuroscience|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CERE
